1. Current Status: Site-Specific Antibody Drug Conjugates
- Author
-
Christian P. R. Hackenberger, Dominik Schumacher, Heinrich Leonhardt, and Jonas Helma
- Subjects
0301 basic medicine ,Drug ,Immunoconjugates ,media_common.quotation_subject ,Immunology ,Computational biology ,Article ,THIOMAB ,03 medical and health sciences ,monomethyl auristatin E/F (MMAE/MMAF) ,Medicine ,Animals ,Humans ,Immunology and Allergy ,tubulin tyrosine ligase (TTL) ,Antibody drug conjugates (ADCs) ,Tub-tag ,therapeutic window ,drug-antibody ratio (DAR) ,unnatural amino acids (UAA) ,formylglycine generating enzyme (FGE) ,Sortase A ,site-specific conjugation ,microbial transglutaminase (MTG) ,Disulfides ,Molecular Targeted Therapy ,Amino Acids ,media_common ,Therapeutic window ,business.industry ,body regions ,Specific antibody ,030104 developmental biology ,Biochemistry ,business ,Conjugate ,Biotechnology - Abstract
Antibody drug conjugates (ADCs), a promising class of cancer biopharmaceuticals, combine the specificity of therapeutic antibodies with the pharmacological potency of chemical, cytotoxic drugs. Ever since the first ADCs on the market, a plethora of novel ADC technologies has emerged, covering as diverse aspects as antibody engineering, chemical linker optimization and novel conjugation strategies, together aiming at constantly widening the therapeutic window for ADCs. This review primarily focuses on novel chemical and biotechnological strategies for the site-directed attachment of drugs that are currently validated for 2nd generation ADCs to promote conjugate homogeneity and overall stability.
- Published
- 2016